Last reviewed · How we verify

NCT05398913: RIMOFATSCI-1

Effects of Rimonabant on Walking Abilities in Incomplete Spinal Cord Injury

Completed Phase 1, PHASE2 Last updated 15 November 2022
What this trial tests

Phase 1, PHASE2 trial testing Rimonabant in Spinal Cord Injuries in 8 participants. Completed in 7 June 2022.

Timeline
12 May 2021
Primary endpoint
7 June 2022
7 June 2022

Quick facts

Lead sponsorHospital Nacional de Parapléjicos de Toledo
PhasePhase 1, PHASE2
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designcrossover
Maskingquadruple
Primary purposetreatment
Enrollment8
Start date12 May 2021
Primary completion7 June 2022
Estimated completion7 June 2022
Sites1 location across Spain

Drugs / interventions tested

Conditions studied

Sponsor

Hospital Nacional de Parapléjicos de Toledo

Who can join

Adults 18 to 65, any sex, with Spinal Cord Injuries. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Randomized placebo-controlled safety and feasibility study with crossover design (3 arms). Placebo or Rimonabant 2.5mg or Rimonabant 5mg will be administered for 5 days. Exploratory efficacy will be tested using six-min walking test.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Rimonabant

Trials testing the same drug.

Other recruiting trials for Spinal Cord Injuries

Currently open trials in the same condition.

Other Hospital Nacional de Parapléjicos de Toledo trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05398913.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing